Hidden Dangers in E-Cigarette Products: A Health Hazard

Aug.08.2024
Hidden Dangers in E-Cigarette Products: A Health Hazard
Duke University researchers reveal tobacco companies substituting unknown, potentially harmful chemicals for nicotine in e-cigarettes to avoid regulations.

According to Mirage News on August 8th, health researchers at Duke University in North Carolina reported that some tobacco companies have started using alternative chemicals with similar characteristics but unknown health impacts to replace nicotine in e-cigarette products in order to circumvent public health regulations.


In a research letter published in the Journal of the American Medical Association on August 7th, researchers from Duke University and Yale University also found that the quantities of these chemicals (known as nicotine analogs) were not accurately disclosed on the packaging.


The study's co-author, Senior Research Scientist Sairam V. Jabba, D.V.M., Ph.D., of Duke University School of Medicine, stated that...


E-cigarette products containing nicotine are restricted by federal law, prohibiting sales to individuals under the age of 21.


Currently, nicotine analogs are not restricted by FDA regulations, and their health effects have not been studied. Our analysis of some e-cigarette products containing analogs sold in the United States found significant and concerning discrepancies between the claimed ingredients and the actual ingredients. Furthermore, manufacturers may be trying to circumvent FDA tobacco regulation.


The study emphasizes that a chemical compound called 6-methyl nicotine is shown in rodent experiments to be more effective and more toxic than nicotine in targeting brain nicotine receptors. Another chemical compound called nicotinamide is advertised as targeting the same brain receptors, although evidence suggests it does not bind to these receptors.


These nicotine analogs are added to flavored e-cigarettes, previous studies have shown that these e-cigarettes are more popular among young people and first-time e-cigarette users.


Jabba and colleagues, including co-senior author Sven Eric Jordt, Ph.D., analyzed a e-cigarette product called Spree Bar, which has at least nine flavors and is labeled as containing 5% 6-methylnicotine. The research findings showed that the actual chemical content was about 88% lower than what was indicated on the label. This e-cigarette also contains an artificial sweetener that is 13,000 times sweeter than sucrose, as well as an artificial cooling agent that mimics the effect of mint.


The second brand of e-cigarette (sold under the names Nixotine, Nixodine, Nixamide, and Nic-Safe) contains a nicotine analogue called niacin, with levels lower than indicated on the label, and combined with an undisclosed amount of 6-methyl nicotine. This brand does not contain any sweeteners or cooling agents.


These products appear to be designed to circumvent laws and regulations aimed at protecting people, especially children, from the harmful effects of smoking and tobacco use. We do not know what effects these chemicals may have when heated and inhaled. These questions should be answered before allowing the products to be marketed.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia’s Ministry of Industry and Trade has proposed extending a voluntary labeling pilot covering reusable e-cigarettes and similar personal electric vaporizing devices until August 31, 2026. A draft government decree has been published on the unified portal for posting drafts of normative legal acts.
Jan.22 by 2FIRSTS.ai
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
Russia’s St. Petersburg Sets Up Working Group to Consider Citywide Vape Sales Ban
Russia’s St. Petersburg Sets Up Working Group to Consider Citywide Vape Sales Ban
Russia’s St. Petersburg legislature has formed a working group to explore tougher controls on vape trade and sales, including the option of a citywide sales ban. The group is set to convene on Jan. 26 with participation from lawmakers, civil society and law enforcement. The move comes as Russia’s federal authorities continue to debate legislation that could allow regions to impose their own restrictions on vapes.
Jan.26 by 2FIRSTS.ai
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam’s Government Decree 371, effective December 31, 2025, stipulates that users of e-cigarettes and heated tobacco products will be fined VND 3–5 million (about $114–$190) and required to destroy the products. The decree also provides that individuals who allow use at premises they own or manage will be fined VND 5–10 million (about $190–$380), with fines doubled for organizations.
Jan.04 by 2FIRSTS.ai
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11